Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms

Creative Commons License

AKBULUT H., Tang Y., Maynard J., Zhang L., Pizzorno G., Deisseroth A.

CLINICAL CANCER RESEARCH, vol.10, no.22, pp.7738-7746, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 22
  • Publication Date: 2004
  • Doi Number: 10.1158/1078-0432.ccr-04-0490
  • Journal Name: CLINICAL CANCER RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.7738-7746
  • Ankara University Affiliated: Yes

Abstract

Purpose: 5-Fluorouracil (5-FU) has been combined in the past with other drugs for the combination chemotherapy for cancers of the breast, ovary, and colon. These drug regimens were limited by the fact that 5-FU fails to kill nondividing cancer cells at the doses that are safe to deliver. The goal of the present study is to test the feasibility of replacing 5-FU in established 5-FU combination chemotherapy with the Ad-LpCDIRESE1A/5-fluorocytosine (5-FC) system for the purpose of reducing toxicity and increasing efficacy.